Skip to main content
. 2025 Jan 7;15:1488175. doi: 10.3389/fendo.2024.1488175

Table 5.

Comparison of PpIX-TSLT variables between patients and matched controls.

All patients and
matched controls
FDR adj.
p value
Trajectory
N=21
FDR-adj.
P value
T0: preoperative
Age (years) controls 40.0 [29.0-64.0]; n=41 0.87 53.0 [31.0-65.0] 0.68
patients 47.0 [37.0-56.0]; n=41 52.0 [37.0-57.0]
Body Mass Index (kg/m²) controls 23.4 [21.3-25.5]; n=41 <0.001 24.1 [21.5-26.0] <0.001
patients 46.3 [42.0-50.8]; n=41 43.6 [41.0-49.3]
MitoPO2 (mmHg) controls 71.3 [59.9-80.9]; n=36 0.25 70.1 [61.3-80.4] 0.29
patients 60.5 [47.8-78.0]; n=36 57.6 [50.0-68.8]
MitoVO2 (mmHg/s) controls 3.6 [2.3-4.8]; n=36 0.86 3.6 [2.9-5.7] 0.97
patients 3.8 [2.4-5.1]; n=36 3.6 [2.4-5.1]
MitoDO2 (mmHg/s) controls 5.7 [4.6-7.6]; n=36 0.002 5.4 [4.3-7.6] 0.29
patients 3.7 [2.4-5.9]; n=36 3.8 [2.7-6.3]
T3: 6 ± 1 months after surgery
MitoPO2 (mmHg) controls 71.0 [59.4-80.6]; n=31 0.64 70.1 [61.3-80.4] 0.29
patients 62.8 [47.9-76.1]; n=31 62.0 [47.9-73.2]
MitoVO2 (mmHg/s) controls 3.7 [2.3-5.6]; n=31 0.86 3.6 [2.9-5.7] 0.74
patients 4.0 [2.9-4.7]; n=31 4.1 [2.6-4.7]
MitoDO2 (mmHg/s) controls 5.6 [4.3-7.3]; n=31 0.64 5.4 [4.3-7.6] 0.68
patients 4.4 [3.2-6.9]; n=31 3.7 [3.0-7.1]
T5: 12 ± 1 months after surgery
MitoPO2 (mmHg) controls 71.3 [60.3-81.9]; n=30 0.86 70.1 [61.3-80.4] 0.78
patients 68.5 [58.8-91.3]; n=30 67.4 [57.8-91.7]
MitoVO2 (mmHg/s) controls 3.4 [2.4-4.5]; n=30 0.64 3.6 [2.9-5.7] 0.29
patients 3.0 [2.3-4.4]; n=30 2.9 [2.1-3.8]
MitoDO2 (mmHg/s) controls 5.6 [4.4-7.3]; n=30 0.43 5.4 [4.3-7.6] 0.68
patients 4.4 [3.2-6.3]; n=30 4.5 [3.4-6.0]

All data in median [interquartile range]. Results are presented for all patients with available data and the trajectory patient sample with available data for all study visits. False-discovery rate adjusted p values < 0.05 (Wilcoxon signed-rank tests) are printed in bold.

mitoPO2, mitochondrial oxygen tension; mitoVO2, mitochondrial oxygen consumption; mitoDO2, mitochondrial oxygen delivery; PpIX-TSLT, Protoporphyrin IX-Triplet State Lifetime Technique.